Literature DB >> 17375073

On the role of CD4+ T cells in the CD8+ T-cell response elicited by recombinant adenovirus vaccines.

Teng Chih Yang1, James Millar, Timothy Groves, Wenzhong Zhou, Natalie Grinshtein, Robin Parsons, Carole Evelegh, Zhou Xing, Yonghong Wan, Jonathan Bramson.   

Abstract

We have investigated the role of CD4(+) T cells in the development of the CD8(+) T-cell response after immunization with recombinant adenovirus (rAd). In the absence of CD4(+) T cells, the "unhelped" CD8(+) T-cell population exhibited a reduction in primary expansion and long-term survival that appeared to be due to inadequate priming of naïve T cells. There were few functional or phenotypic differences between the helped and unhelped CD8(+) T-cell populations with the exception of O-glycosylated CD43, a marker of effector cells, which was augmented on the unhelped CD8(+) T-cell population. In some cases, the unhelped CD8(+) T-cell population exhibited reduced ability to control virus infection; however, this appeared to be a function of the reduced frequency of antigen-specific CD8(+) T cells. Most notably, the unhelped CD8(+) T-cell population exhibited no defect in secondary expansion. These results provide insight into the role of CD4(+) T cells during the primary CD8(+) T-cell response generated by rAd vaccines and identify potential benefits and issues that must be considered when using adenovirus vaccines under conditions where CD4(+) T-cell function may be limiting, such as vaccination of human immunodeficiency virus patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17375073     DOI: 10.1038/sj.mt.6300130

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  21 in total

1.  Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.

Authors:  Geert Leroux-Roels; Patricia Bourguignon; Julie Willekens; Michel Janssens; Frédéric Clement; Arnaud M Didierlaurent; Laurence Fissette; François Roman; Dominique Boutriau
Journal:  Clin Vaccine Immunol       Date:  2014-01-03

Review 2.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

3.  Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus.

Authors:  Jonathan D Finn; Jennifer Bassett; James B Millar; Natalie Grinshtein; Teng Chih Yang; Robin Parsons; Carole Evelegh; Yonghong Wan; Robin J Parks; Jonathan L Bramson
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

4.  Adenovirus Serotype 5 Vaccination Results in Suboptimal CD4 T Helper 1 Responses in Mice.

Authors:  Junghwa Lee; Masao Hashimoto; Se Jin Im; Koichi Araki; Hyun-Tak Jin; Carl W Davis; Bogumila T Konieczny; Gregory A Spies; M Juliana McElrath; Rafi Ahmed
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

5.  Combined mTOR inhibition and OX40 agonism enhances CD8(+) T cell memory and protective immunity produced by recombinant adenovirus vaccines.

Authors:  Jennifer D Bassett; Stephanie L Swift; Heather VanSeggelen; Joanne A Hammill; A J Robert McGray; Carole Evelegh; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

6.  Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4+ T cell responses that impair CD8+ T cell function.

Authors:  Rafael A Larocca; Nicholas M Provine; Malika Aid; M Justin Iampietro; Erica N Borducchi; Alexander Badamchi-Zadeh; Peter Abbink; David Ng'ang'a; Christine A Bricault; Eryn Blass; Pablo Penaloza-MacMaster; Kathryn E Stephenson; Dan H Barouch
Journal:  Sci Immunol       Date:  2016-11-04

7.  Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.

Authors:  Nicholas M Provine; Rafael A Larocca; Pablo Penaloza-MacMaster; Erica N Borducchi; Anna McNally; Lily R Parenteau; David R Kaufman; Dan H Barouch
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

8.  Immediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells.

Authors:  Nicholas M Provine; Rafael A Larocca; Malika Aid; Pablo Penaloza-MacMaster; Alexander Badamchi-Zadeh; Erica N Borducchi; Kathleen B Yates; Peter Abbink; Marinela Kirilova; David Ng'ang'a; Jonathan Bramson; W Nicholas Haining; Dan H Barouch
Journal:  J Immunol       Date:  2016-07-22       Impact factor: 5.422

9.  Dendritic cell based genetic immunization stimulates potent tumor protection dependent on CD8 CTL cells in the absence of autoimmunity.

Authors:  Sheng Zhang; Weiyi Huang
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-26       Impact factor: 4.553

10.  Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.

Authors:  Kylie M Quinn; Andreia Da Costa; Ayako Yamamoto; Dana Berry; Ross W B Lindsay; Patricia A Darrah; Lingshu Wang; Cheng Cheng; Wing-Pui Kong; Jason G D Gall; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Emma Gostick; David A Price; Carmen E Gomez; Mariano Esteban; Linda S Wyatt; Bernard Moss; Cecilia Morgan; Mario Roederer; Robert T Bailer; Gary J Nabel; Richard A Koup; Robert A Seder
Journal:  J Immunol       Date:  2013-02-06       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.